Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a

References

• Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310–6
   PubMed Web of Science ®Google Scholar
• Schennach H, Schoenitzer D, Fuchs D. Association between chronic hepatitis C virus infection and increased neopterin concentrations in blood donations. Clin Chem 1998; 44: 2225–6
   PubMed Web of Science ®Google Scholar
• Grungreiff K, Reinhold D, Ansorge S. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine 1999; 11: 1076–80
   PubMed Web of Science ®Google Scholar
• Weiss G, Umlauft F, Urbanek M, Herold M, Lovevsky M, Offner F, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999; 180: 1452–8
   PubMed Web of Science ®Google Scholar
• Quiroga JA, Martin J, Pardo M, Carreno V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci 1994; 39: 2485–96
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Auhuber I, Fuchs D, Hausen A, Judmaier G, Prior C, et al. Urinary neopterin levels in acute viral hepatitis. Hepatology 1988; 8: 771–4
   PubMed Web of Science ®Google Scholar
• Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319–29
   PubMed Web of Science ®Google Scholar
• Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 2005; 40: 853–8
   PubMed Web of Science ®Google Scholar
• Zheng B, Cao KY, Chan CP, Choi JW, Leung W, Leung M, et al. Serum neopterin for early assessment of severity of severe acute respiratory syndrome. Clin Immunol 2005; 116: 18–26
   PubMed Web of Science ®Google Scholar
• Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000; 119: 479–85
   PubMed Web of Science ®Google Scholar
• Amirayan-Chevillard N, Tissot-Dupont H, Obadia Y, Gallais H, Mege JL, Capo C. Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin. Clin Diagn Lab Immunol 2000; 7: 832–4
   PubMedGoogle Scholar
• Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334: 1011–7
   PubMed Web of Science ®Google Scholar
• Daniel V, Susal C, Melk A, Weimer R, Kropelin M, Zimmermann R, et al. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients. Immunol Lett 1999; 69: 283–9
   PubMed Web of Science ®Google Scholar
• van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, Buller HR, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 693–8
   PubMed Web of Science ®Google Scholar
• Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997; 107: 359–63
   PubMed Web of Science ®Google Scholar
• de Metz J, Sprangers F, Endert E, Ackermans MT, ten Berge IJ, Sauerwein HP, et al. Interferon-gamma has immunomodulatory effects with minor endocrine and metabolic effects in humans. J Appl Physiol 1999; 86: 517–22
   PubMed Web of Science ®Google Scholar
• Fuchs D, Norkrans G, Wejstal R, Reibnegger G, Weiss G, Weiland O, et al. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med 1992; 1: 196–200
   PubMedGoogle Scholar
• Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563–70
   PubMed Web of Science ®Google Scholar
• Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556–67
   PubMed Web of Science ®Google Scholar
• Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′-nontranslated region are essential for virus replication in vivo. J Virol 2000; 74: 2046–51
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997–1002
   PubMed Web of Science ®Google Scholar
• Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640–8
   PubMed Web of Science ®Google Scholar
• Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature 2005; 436: 930–2
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215–29
   PubMed Web of Science ®Google Scholar
• Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol 2005; 15: 235–68
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631–9
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767–77
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002; 2: 675–87
   PubMed Web of Science ®Google Scholar
• Biezeveld MH, van Mierlo G, Lutter R, Kuipers IM, Dekker T, Hack CE, et al. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin Exp Immunol 2005; 141: 183–8
   PubMed Web of Science ®Google Scholar
• Gale M, Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939–45
   PubMed Web of Science ®Google Scholar